In summary, our research identifies PDLIM4 as a facilitator of malignant progression and DDP resistance in GC cells, targeting PDLIM4 not only inhibits the malignant progression of GC, but also provides an effective strategy to enhance DDP sensitivity in GC treatment, emphasizing its potential as a therapeutic target. Here, PDLIM4 is linked to gastric cancer.